Mentice AB (MNTC)

Mentice AB (publ) provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas. The company operates through three segments: Systems, Software Licenses and Service. It offers software modules in the areas of acute ischemic stroke intervention, atrial septal defect and patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee intervention, carotid intervention, patient-specific simulation, coronary advanced, essential, and intermediate, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic artery embolization, radiation safety, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, peripheral angiography, and vascular trauma and cardiac rhythm management, as well as supports interventionalists to transition from transfemoral to transradial access. The company also provides simulator accessories and extensions for endovascular therapies; cardiovascular; neurovascular; peripheral vascular solutions; mentice right heart cath app, a mobile solution for an interactive real-time exploration into the right heart catheterization procedure; mentice live learning center, a cloud based learning center for medical technology industry and healthcare provider; and angio suites and robotic integrators. Mentice AB (publ) was incorporated in 1998 and is headquartered in Gothenburg, Sweden.